| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Weill Medical College of Cornell University, New York, New York, USA
Key Words. Angiogenesis • Epidermal growth factor receptor • Monoclonal antibodies • Bevacizumab • Cetuximab
Correspondence: Ki Young Chung, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-6121; Fax: 646-422-2246; e-mail: chungk{at}mskcc.org
The recent successful development of novel monoclonal antibodies that target key components of biologic pathways has expanded the armamentarium of treatment options for patients with colorectal cancer. Two targets in particular–the process of new blood vessel development, or angiogenesis, and the epidermal growth factor receptor and its signaling pathway–are exploited by the newest monoclonal antibodies that are available for use in colorectal cancer patients. This clinical review focuses on the defining role of the two most clinically advanced novel agents, bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA, http://www.gene.com) and cetuximab (Erbitux®; ImClone Systems, Inc., New York, http://www.imclone.com), in colorectal cancer.
This article has been cited by other articles:
 |
|
 |
|
  C. Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. Mazzocchi, F. Arienti, et al. Induction of Both CD8+ and CD4+ T-Cell-Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1 Clin. Cancer Res., November 15, 2008; 14(22): 7292 - 7303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Prewett, D. S. Deevi, R. Bassi, F. Fan, L. M. Ellis, D. J. Hicklin, and J. R. Tonra Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab Clin. Cancer Res., December 15, 2007; 13(24): 7432 - 7440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-P Machiels, C Sempoux, P Scalliet, J-C Coche, Y Humblet, E Van Cutsem, J Kerger, J-L Canon, M Peeters, S Aydin, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann. Onc., April 1, 2007; 18(4): 738 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman, and B. Gilks Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment Ann. Surg. Oncol., February 1, 2007; 14(2): 719 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Hahn, J. J. Wolff, and J. M. Kolesar Pharmacogenetics and irinotecan therapy Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2211 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mimeault and S. K. Batra Concise Review: Recent Advances on the Significance of Stem Cells in Tissue Regeneration and Cancer Therapies Stem Cells, November 1, 2006; 24(11): 2319 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Lenz, E. Van Cutsem, S. Khambata-Ford, R. J. Mayer, P. Gold, P. Stella, B. Mirtsching, A. L. Cohn, A. W. Pippas, N. Azarnia, et al. Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines J. Clin. Oncol., October 20, 2006; 24(30): 4914 - 4921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nagorsen and E. Thiel Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Adams Evolving role of antineoplastic agents in colorectal cancer Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S4 - S11. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
